• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.01%

    Aerie Pharmaceuticals, Inc. (AERI)

    18.14 Up 0.23(1.28%) Jul 31, 4:00PM EDT
    |After Hours : 17.95 Down 0.19 (1.06%) Jul 31, 5:36PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Aerie Pharmaceuticals, Inc.
    2030 Main Street
    Suite 1500
    Irvine, CA 92614
    United States - Map
    Phone: 949-526-8700
    Fax: 949-526-8787
    Website: http://www.aeriepharma.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Major
    Full Time Employees:40

    Business Summary 

    Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its product candidates include Rhopressa, which is a once-daily eye drop that reduces intraocular pressure (IOP) in patients with glaucoma or ocular hypertension and is in Phase III registration trials; and Roclatan, a once-daily eye drop to reduce IOP that has completed Phase IIb clinical trial in patients with open-angle glaucoma and ocular hypertension. The company also provides AR-13533, a second-generation ROCK/NET inhibitor that offers additional IOP-lowering effect in patients with glaucoma is in preclinical studies. Aerie Pharmaceuticals, Inc. was founded in 2005 and is based in Irvine, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Aerie Pharmaceuticals, Inc.

    Corporate Governance 
    Aerie Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jul 1, 2015 is 9. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Vicente Anido Jr., Ph.D., 62
    Chairman and Chief Exec. Officer
    Mr. Thomas A. Mitro , 57
    Pres and Chief Operating Officer
    Mr. Richard J. Rubino CPA, 57
    Chief Financial Officer and Sec.
    Dr. Casey C. Kopczynski Ph.D. , 54
    Co-Founder and Chief Scientific Officer
    Mr. Craig R. Skenes ,
    VP of Bus. Devel.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders